Lab
ST Lukes Hospital of Kansas City
ST Lukes Hospital of Kansas City was paid $18.71M by Medicaid between Jan 2018 and Dec 2024, across 169 billing codes. Its largest line is X4011, State-specific procedure code — 15% of everything it billed.
33Billing provider infoST LUKES HOSPITAL OF KANSAS CITY
KANSAS CITY, MO 64111
KANSAS CITY, MO 64111
33aNPI1063494177assigned 11/15/2005
33bProvider typeClinical Medical Laboratory
28Total paid$18.71M
24GClaims362,521
24DCodes billed169
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Missouri
Rank by total paid#2 of 61
Median peer was paid$85K
This provider vs. median221×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 50,580 | $5.67M | |
| 2019 | 37,691 | $2.95M | |
| 2020 | 28,774 | $1.63M | |
| 2021 | 52,013 | $1.17M | |
| 2022 | 58,155 | $2.08M | |
| 2023 | 74,677 | $2.95M | |
| 2024incomplete | 60,631 | $2.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| X4011 | State-specific procedure code | 15% | 8,245 | 7,601 | $2.82M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 13% | 35,859 | 29,866 | $2.45M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 10,443 | 9,803 | $1.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.4% | 11,277 | 10,594 | $1.39M |
| H2018 | Psychosocial rehabilitation services, per diem | 5.1% | 18,394 | 651 | $946K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.0% | 37,403 | 32,789 | $935K |
| 80053 | Comprehensive metabolic panel | 4.3% | 31,540 | 27,981 | $802K |
| 81002 | 2.9% | 23,611 | 18,802 | $552K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 2.5% | 7,469 | 7,218 | $469K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.3% | 13,241 | 10,916 | $432K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.2% | 5,045 | 4,498 | $403K |
| 76818 | 1.9% | 6,305 | 4,140 | $360K |
157 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 3,869 | $315K |
| X4003 | 1.5% | 2,837 | $284K | |
| X4006 | 1.5% | 137 | $284K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 2,107 | $238K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.1% | 2,316 | $204K |
| 59025 | Fetal non-stress test | 1.1% | 1,956 | $197K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 3,765 | $194K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,676 | $172K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,617 | $172K |
| 86850 | <1% | 4,776 | $163K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,431 | $158K |
| 85027 | <1% | 6,303 | $154K | |
| 86592 | <1% | 4,900 | $137K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,798 | $136K |
| Y7506 | <1% | 934 | $110K | |
| 81025 | <1% | 1,450 | $95K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,015 | $91K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,832 | $83K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,192 | $82K |
| 76820 | <1% | 1,106 | $75K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,321 | $72K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,644 | $72K |
| 81003 | <1% | 2,677 | $72K | |
| 77386 | <1% | 296 | $71K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 518 | $68K |
| 86803 | <1% | 3,480 | $68K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,851 | $66K |
| 84484 | <1% | 1,093 | $63K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,428 | $63K |
| 81513 | <1% | 558 | $61K | |
| 86900 | <1% | 2,002 | $57K | |
| 80061 | Lipid panel | <1% | 4,881 | $54K |
| 86901 | <1% | 2,004 | $50K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,771 | $49K |
| 77334 | <1% | 101 | $46K | |
| 87340 | <1% | 2,032 | $43K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 877 | $40K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,968 | $39K |
| 83690 | <1% | 470 | $38K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,611 | $36K |
| 80081 | <1% | 657 | $35K | |
| 77412 | <1% | 161 | $34K | |
| 86762 | <1% | 1,157 | $31K | |
| 82950 | <1% | 2,143 | $30K | |
| 81001 | <1% | 783 | $29K | |
| 86481 | <1% | 394 | $28K | |
| 62323 | <1% | 94 | $28K | |
| 87660 | <1% | 2,169 | $27K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 321 | $27K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,151 | $24K |
| 80305 | <1% | 234 | $24K | |
| 77336 | <1% | 379 | $23K | |
| 87480 | <1% | 1,669 | $22K | |
| 82728 | <1% | 2,125 | $21K | |
| 84702 | <1% | 333 | $20K | |
| 82607 | <1% | 1,890 | $19K | |
| 86480 | <1% | 383 | $18K | |
| 84466 | <1% | 1,918 | $17K | |
| 86780 | <1% | 1,900 | $16K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 261 | $16K |
| 87481 | <1% | 534 | $15K | |
| 87081 | <1% | 2,285 | $14K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 170 | $13K |
| 87497 | <1% | 879 | $13K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 202 | $13K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 213 | $12K |
| 87799 | <1% | 842 | $12K | |
| 84439 | <1% | 1,967 | $12K | |
| 82746 | <1% | 1,118 | $11K | |
| Y7507 | <1% | 135 | $11K | |
| 99285 | Emergency room visit (most serious) | <1% | 29 | $11K |
| 83540 | <1% | 2,142 | $10K | |
| 87510 | <1% | 804 | $10K | |
| 85610 | <1% | 1,282 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 248 | $9K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 323 | $9K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 264 | $9K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 196 | $8K |
| 87077 | <1% | 1,304 | $8K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 69 | $7K |
| 83735 | <1% | 2,178 | $6K | |
| 80069 | <1% | 1,778 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 51 | $5K |
| 80197 | <1% | 1,179 | $5K | |
| 84403 | <1% | 230 | $5K | |
| 82105 | <1% | 203 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 89 | $4K |
| 83021 | <1% | 28 | $4K | |
| 87186 | <1% | 639 | $4K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 13 | $3K |
| 84481 | <1% | 245 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 67 | $3K |
| J3490 | Unclassified drugs | <1% | 435 | $3K |
| 83001 | <1% | 192 | $3K | |
| 82570 | <1% | 719 | $2K | |
| 82670 | <1% | 114 | $2K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 171 | $2K |
| 82043 | <1% | 592 | $2K | |
| 86140 | <1% | 570 | $2K | |
| 20610 | <1% | 14 | $2K | |
| 86038 | <1% | 232 | $2K | |
| 84156 | <1% | 1,402 | $2K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 27 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 44 | $2K |
| 84153 | <1% | 131 | $2K | |
| 76801 | <1% | 52 | $2K | |
| 86336 | <1% | 25 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 40 | $2K |
| 86300 | <1% | 41 | $1K | |
| 77300 | <1% | 15 | $1K | |
| 87015 | <1% | 208 | $1K | |
| Q3014 | Telehealth originating site facility fee | <1% | 139 | $1K |
| 85652 | <1% | 466 | $913.16 | |
| 82677 | <1% | 12 | $880.32 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 33 | $870.10 |
| 83605 | <1% | 81 | $657.90 | |
| 83020 | <1% | 159 | $616.35 | |
| 36591 | <1% | 14 | $581.00 | |
| 84146 | <1% | 42 | $577.94 | |
| 84163 | <1% | 13 | $445.76 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 16 | $389.80 |
| 84425 | <1% | 25 | $377.63 | |
| 83880 | <1% | 13 | $302.23 | |
| 82977 | <1% | 71 | $297.75 | |
| 81015 | <1% | 133 | $294.18 | |
| 82951 | <1% | 26 | $255.81 | |
| 86706 | <1% | 32 | $241.51 | |
| 80076 | <1% | 43 | $235.01 | |
| 84144 | <1% | 18 | $234.17 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,265 | $201.13 |
| 84100 | <1% | 72 | $200.86 | |
| 86696 | <1% | 12 | $171.44 | |
| 82784 | <1% | 13 | $167.96 | |
| 83002 | <1% | 12 | $162.91 | |
| 86376 | <1% | 13 | $151.32 | |
| 85384 | <1% | 17 | $138.52 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 42 | $134.88 |
| 85730 | <1% | 29 | $120.98 | |
| 86695 | <1% | 12 | $116.84 | |
| 87147 | <1% | 12 | $111.78 | |
| 82962 | <1% | 52 | $103.53 | |
| 86431 | <1% | 14 | $63.42 | |
| 82550 | <1% | 23 | $60.94 | |
| 87210 | <1% | 12 | $51.15 | |
| 82952 | <1% | 13 | $37.56 | |
| 84460 | <1% | 24 | $26.55 | |
| 84075 | <1% | 24 | $25.95 | |
| 84450 | <1% | 24 | $25.94 | |
| 82248 | <1% | 12 | $25.15 | |
| 82247 | <1% | 24 | $25.15 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 35 | $21.34 |
| 84155 | <1% | 24 | $18.50 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13 | $10.60 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18 | $3.61 |
| A9270 | Non-covered item or service | 0% | 30 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 13 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 47 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNACHTIGAL, AMY (VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| ST Lukes Hospital of Kansas City | Kansas City, MO | $5.62M |
| Medical Plaza Imaging Associates, LLC | Kansas City, MO | $129K |
| ST. Luke's Hospital of Kansas City | Kansas City, MO | $120K |
| ST. Luke's Hospital of Kansas City | Kansas City, MO | $362.82 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.